The Cancer Control &Population Sciences Program (CCPS) organizes all of the cancer prevention-related research activities of the Winship Cancer Institute (WCI), which span the cancer prevention continuum from primary to secondary to tertiary prevention at the individual, select population, and societal levels. The overall goals of the Program are to reduce cancer risk, incidence, morbidity, and mortality in Georgia through describing and tracking cancer incidence and mortality trends of all cancers;conducting etiologic research in humans;conducting chemoprevention trials in Georgia and in national collaborations;applying theories of human behavior to prevent cancer through early detection;conducting multi-disciplinary research that describes, interprets, and predicts the impact of interventions and other factors on cancer outcomes important to decision makers;characterizing the scope of behavioral co-morbidities that occur in patients with cancer;and understanding relevant mechanisms and treatments of these behavioral co-morbidities. To promote the development of the different areas of research associated with cancer control and population sciences across the entire prevention continuum, and to do so in a coordinated manner, the program is organized into four general research areas, each headed by a senior investigator: 1) Epidemiology, Biomarkers &Chemoprevention (EBC);2) Health Behavior Research (HBR);3) Outcomes &Quality (OQ);and 4) Symptom Management &Control (SMC). The CCPS Program includes members from 17 departments across all three schools in the health sciences at Emory University?Public Health, Nursing, and Medicine?and the Emory College. Beginning with few members and little funding at the start of the P20, through recruitment and internal development, the Program now has 62 members, of whom 41 are Core, eight Research, eight Clinical, and five Coalition, and a portfolio of 52 NIH and other national, peerreviewed, cancer-related grants headed by 25 Core members, with a combined funding for this year of $9,931,319 in Program direct costs (out of a total of 84 externally-funded cancer research grants with $12,185,701 in Program total costs). The number of peer-reviewed cancer publications by members of the Program during the last grant period was 455 of which 22% were intra-programmatic and 7.5% were interprogrammatic?proportions that are rapidly escalating in this young program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA138292-01
Application #
7944891
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-07
Project End
2012-03-31
Budget Start
2009-04-07
Budget End
2010-03-31
Support Year
1
Fiscal Year
2009
Total Cost
$79,819
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Morgan, T M; Wang, X; Qian, X et al. (2018) Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. Clin Transl Oncol :
Lin, Songbai; Han, Yiran; Jenkin, Kayte et al. (2018) Lysophosphatidic Acid Receptor 1 Is Important for Intestinal Epithelial Barrier Function and Susceptibility to Colitis. Am J Pathol 188:353-366
Zhu, Dan; Osuka, Satoru; Zhang, Zhaobin et al. (2018) BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell 33:1004-1016.e5
Bekhbat, Mandakh; Chu, Karen; Le, Ngoc-Anh et al. (2018) Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology 98:222-229

Showing the most recent 10 out of 331 publications